## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($174.91)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. California Public Employees Retirement System Reduces Stake in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251209T101905 | Neutral | Relevance: 98%
- The California Public Employees Retirement System (CalPERS) has reduced its stake in Quest Diagnostics (NYSE:DGX) by 17.3% during the second quarter, selling 85,008 shares and holding 406,276 shares worth $72.98 million. Despite this, institutional investors and hedge funds still own 88.06% of the stock. Analysts have a "Moderate Buy" rating for Quest Diagnostics with an average price target of $196.31, while company insiders have recently sold over 94,000 shares.

**2. What Labcorp Holdings (LH)'s Slowing Growth and Margin Pressure Means For Shareholders**
- Source: Simply Wall Street | 20251211T032445 | Neutral | Relevance: 62%
-  Labcorp Holdings is facing challenges including persistently slow organic sales growth, declining adjusted operating margins, and a weaker return on invested capital. The company may need to reassess its cost structure and capital allocation strategies to address investor concerns about its profitability and growth opportunities. Despite these issues, Labcorp's ventures into precision oncology and digital pathology, including new ctDNA tests and AI collaborations, are seen as potential avenues for higher-value growth that could offset slower organic performance and aid margin recovery.

**3. Is CapsoVision Showing How Far A Single Capsule Can Take A Med-Tech Company?**
- Source: RTTNews | 20251211T090957 | Somewhat-Bullish | Relevance: 61%
-  CapsoVision Inc. (CV) has garnered significant attention following a sharp rise in trading activity and share price, closing up 32.73% and continuing to climb in after-hours trading. The company, which specializes in endoscopic video imaging devices for GI visualization, is expanding its commercial footprint with products like CapsoCam Plus and advancing new clinical programs such as a Breakthrough Device Designation application for pancreatic cancer detection. CapsoVision's strong financial performance, strategic partnerships, and technological advancements position it as a company to watch in the medical technology sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 17.5x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.3B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 17.5 |
| Current P/E | 18.5 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.0% to -1.1% (+2.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.92), momentum weakening. RSI neutral at 45.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.05% (CS: 26) | Neutral |
| RSI_14 | 44.9 | Neutral |
| MACD Histogram | -0.92 | Bearish |
| vs SMA20 | 0.979x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 1.026x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $181.57
- **Stop Loss:** $174.91 (3.7% risk)
- **Target:** $188.23 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 207
- **Position Value:** $37,584.99
- **Portfolio %:** 37.58%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*